Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tarsus PharmaceuticalsTARS -0.72%46 Equity-to-Asset is 0.60 as of Mar. 2026, which is 24% below its 10-year median of 0.79. GuruFocus rates TARS with a GF Score™ of 46/100 and a GF Value™ of $209.50 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,415 Biotechnology companies, Tarsus Pharmaceuticals ranks worse than 58.94% on this metric.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Tarsus Pharmaceuticals Equity-to-Asset Related Terms
Tarsus Pharmaceuticals Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Tarsus Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TARS vs VERA, BEAM, KOD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Tarsus Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsus Pharmaceuticals Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tarsus Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Tarsus Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Tarsus Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsus Pharmaceuticals (TARS) has a Equity-to-Asset of 0.60 as of Mar. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tarsus Pharmaceuticals and its competitors. This is 24% below median its historical median of 0.79. According to the industry distribution chart, Tarsus Pharmaceuticals ranks #834 out of 1415 companies in the Biotechnology industry, placing it in the top 58.9%.
Is Tarsus Pharmaceuticals' Equity-to-Asset too high?
Tarsus Pharmaceuticals' current Equity-to-Asset of 0.60 is 24% below median its 10-year median of 0.79. The Biotechnology industry median Equity-to-Asset is 0.68. Tarsus Pharmaceuticals' value of 0.60 is 11.8% below this industry median. Based on the distribution chart, Tarsus Pharmaceuticals ranks #834 out of 1415 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Tarsus Pharmaceuticals has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tarsus Pharmaceuticals' Equity-to-Asset compare to VERA and BEAM?
According to the Biotechnology industry distribution chart, Tarsus Pharmaceuticals ranks #834 out of 1415 companies for Equity-to-Asset. This places Tarsus Pharmaceuticals in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Tarsus Pharmaceuticals' value of 0.60 is 11.8% below this benchmark. While the company's 10-year median is 0.79 vs. the industry median of 0.68, Tarsus Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsus Pharmaceuticals's current Equity-to-Asset of 0.60 is 11.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Tarsus Pharmaceuticals and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsus Pharmaceuticals's current Equity-to-Asset is 0.60, which is 24% below median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals (TARS) is currently considered Possible Value Trap. The stock's GF Value™ is $209.50, compared to a current price of $58.48 — trading 72.1% below its estimated fair value. The current Equity-to-Asset is 0.60, which is 24% below median its 10-year median of 0.79 and 11.8% below the Biotechnology industry median of 0.68. Tarsus Pharmaceuticals' overall GF Score™ is 46/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Tarsus Pharmaceuticals (TARS), the current Equity-to-Asset is 0.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsus Pharmaceuticals (TARS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsus Pharmaceuticals stock appears to be undervalued.
The current stock price of $58.48 is trading 72.1% below its estimated GF Value™ of $209.50.
GuruFocus considers Tarsus Pharmaceuticals to be Possible Value Trap.
Key valuation signals for TARS:
Equity-to-Asset: 0.60 (24% below median its 10-year median of 0.79)
GF Value™: $209.50 vs. price of $58.48 (72.1% below fair value)
Industry Position: 11.8% below the Biotechnology median (#834 of 1415)
No single metric tells the full story. See the TARS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
46GF Score
Get the complete analysis for TARS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TARS has been successfully added to your 
